Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis Results of the Ege study - Archive ouverte HAL Access content directly
Journal Articles Clinical Neurology and Neurosurgery Year : 2018

Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis Results of the Ege study

(1) , , (2) , (3) , (4, 5, 6) , , , (7) , , , , , , , , , , , ,
1
2
3
4
5
6
7
Oguz Reşat Sipahi
  • Function : Correspondent author
Sinan Mermer
  • Function : Author
Selin Bardak Ozcem
  • Function : Author
Şafak Kaya
  • Function : Author
Cemal Bulut
  • Function : Author
Recep Tekin
  • Function : Author
Hasip Kahraman
  • Function : Correspondent author
Erkin Özgiray
  • Function : Author
Taşkin Yurtseven
  • Function : Author
Hilal Sipahi
  • Function : Correspondent author
Bilgin Arda
  • Function : Author
Hüsnü Pullukçu
  • Function : Author
Meltem Taşbakan
  • Function : Author
Tansu Yamazhan
  • Function : Author
Sohret Aydemir
  • Function : Author
Sercan Ulusoy
  • Function : Author

Abstract

Objectives - In this study we retrospectively reviewed A. baumannii meningitis cases treated with tigecycline including regimens and evaluated the efficacy of tigecycline in the therapy. Patients and methods - Study was performed in seven tertiary-care educational hospitals from five cities of Turkey and one center from France. We extracted data and outcomes of all adult (aged >18) patients with culture proven A. baumannii meningitis treated with tigecycline including antibiotic therapy until April 2016. Results - A total of 23 patients (15 male and eight female) fulfilled our inclusion criteria. All Acinetobacter strains were carbapenem-resistant and susceptible to tigecycline. Six cases received tigecycline monotherapy while 17 received tigecycline including combination therapy (10 with colistin, 4 with netilmicin, 3 with amikacin, 4 with meropenem). Seven of 23 cases (30%) died during the tigecycline including therapy (1 in monotherapy, 4 in colistin, 2 in netilmicin, 1 amikacin, one case received tigecycline + netilmicin followed by tigecycline + colistin). Hence, overall end of treatment (EOT) success was 70%. However, since further 27% died due to additional nosocomial infections, overall clinical success (relieved symptoms at the EOT and one-month post-therapy survival without any relapse or reinfection) decreased to 43%.Conclusion - We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multidrug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.
Fichier principal
Vignette du fichier
Sipahi et al_Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii.pdf (709.25 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01833940 , version 1 (13-07-2018)
hal-01833940 , version 2 (14-09-2018)

Identifiers

Cite

Oguz Reşat Sipahi, Sinan Mermer, Tuna Demirdal, Aslihan Candevir Ulu, Pierre Fillâtre, et al.. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis Results of the Ege study. Clinical Neurology and Neurosurgery, 2018, 172, pp.31-38. ⟨10.1016/j.clineuro.2018.06.008⟩. ⟨hal-01833940v2⟩
349 View
365 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More